Isoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010.

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA (2000) 8.42

Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis (2001) 3.88

Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev (2006) 3.79

Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis (1986) 3.46

Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2002) 3.06

Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med (2009) 3.05

Does DOTS work in populations with drug-resistant tuberculosis? Lancet (2005) 2.95

Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis (2003) 2.92

The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis (2004) 2.64

Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax (2012) 2.39

Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis (1991) 2.37

Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis (2009) 2.25

Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med (1997) 2.18

Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med (2000) 2.11

Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis (2007) 1.76

Gender differentials of pulmonary tuberculosis transmission and reactivation in an endemic area. Thorax (2006) 1.45

Tuberculosis-related deaths within a well-functioning DOTS control program. Emerg Infect Dis (2002) 1.42

Comparison of variable number tandem repeat and IS6110-restriction fragment length polymorphism analyses for discrimination of high- and low-copy-number IS6110 Mycobacterium tuberculosis isolates. J Clin Microbiol (2001) 1.41

Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect (2010) 1.26

The role of core groups in transmitting Mycobacterium tuberculosis in a high prevalence community in Southern Mexico. Int J Tuberc Lung Dis (2000) 1.18

Large outbreak of isoniazid-monoresistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. Euro Surveill (2011) 1.11

Relatively low primary drug resistant tuberculosis in southwestern Ethiopia. BMC Res Notes (2012) 1.10

Tuberculosis in ageing: high rates, complex diagnosis and poor clinical outcomes. Age Ageing (2012) 0.97

Drug resistance in Mexico: results from the National Survey on Drug-Resistant Tuberculosis. Int J Tuberc Lung Dis (2013) 0.95

Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. PLoS One (2014) 0.95

Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect (2014) 0.91

A retrospective analysis of isoniazid-monoresistant tuberculosis: among Iranian pulmonary tuberculosis patients. Open Microbiol J (2014) 0.90

Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis (2011) 0.86

Treatment of drug-resistant tuberculosis. Infect Drug Resist (2011) 0.85

First national survey of Mycobacterium tuberculosis drug resistance, Madagascar, 2005-2006. Int J Tuberc Lung Dis (2010) 0.83

High isoniazid resistance rates in rifampicin susceptible Mycobacterium tuberculosis pulmonary isolates from Pakistan. PLoS One (2012) 0.83

Primary drug resistance in a region with high burden of tuberculosis. A critical problem. Salud Publica Mex (2015) 0.80

Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. PLoS One (2016) 0.78

[Primary resistance to anti tuberculosis drugs in Chile 2011-2012]. Rev Chilena Infectol (2015) 0.77

Association of Pulmonary Tuberculosis and Diabetes in Mexico: Analysis of the National Tuberculosis Registry 2000-2012. PLoS One (2015) 0.84

Results of the implementation of a pilot model for the bidirectional screening and joint management of patients with pulmonary tuberculosis and diabetes mellitus in Mexico. PLoS One (2014) 0.81

Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series. PLoS One (2015) 0.81

Molecular clustering of patients with diabetes and pulmonary tuberculosis: A systematic review and meta-analysis. PLoS One (2017) 0.75